The discovery of novel immune checkpoints has marked a significant advancement in the field of cancer immunotherapy, offering new targets and therapeutic strategies beyond traditional checkpoints like CTLA-4 and PD-1/PD-L1 [152]. The gene discussed is CTLA4; the disease is cancer.